Picture Source: https://www.ibi-ag.com/

IBI Ag, an innovative leader in crop protection, has successfully closed the first part of its Series A funding round with a $6.1 million investment. Led by Corteva Inc. through the Corteva Catalyst platform, with participation from The Trendlines Group, Iron Nation, Consensus Business Group (CBG), and a grant from the Israel Innovation Authority, this investment underscores the growing importance of biological crop protection solutions in the global agricultural sector.

IBI Ag’s groundbreaking technology leverages single-domain antibodies (VHHs) to produce highly effective bio-insecticides with a significantly lower ecological footprint. Adapted from pharmaceutical technology and optimized for agriculture, this new approach targets a wide range of insect pests—including sucking and chewing insects—while minimizing impact on non-target organisms. The company is initially focusing on high-value crops, with plans to expand into row crops in the future.

Innovative Single-Domain Antibody Technology for Sustainable Crop Protection

“We are excited to have the backing of both our existing and new investors, led by Corteva,” said Arnon Heyman, CEO of IBI Ag. “This funding will enable us to accelerate the development of our single-domain antibody technology, bringing farmers sustainable, effective crop protection solutions. Our VHH technology represents a significant advancement in agricultural pest control, offering a novel mode of action that could revolutionize how we protect crops and preserve the environment.”

The investment supports IBI Ag’s mission to develop next-generation bioinsecticides that work in harmony with the environment, offering an alternative to traditional chemical pesticides. By utilizing single-domain antibodies, IBI Ag aims to provide a highly specific and environmentally friendly solution to pest control that targets only harmful insects, leaving beneficial species unharmed.

Corteva Inc. Sees Strong Potential in IBI Ag's Bio-Insecticides

“We see considerable potential in IBI Ag’s bioinsecticide solutions as a smart, sustainable option for farmers looking to manage insect pests without harming the environment,” said Tom Greene, Senior Director at Corteva Inc. and Global Leader for Corteva Catalyst. “This investment aligns with our commitment to advancing innovative solutions for sustainable agriculture, and we believe IBI Ag’s use of single-domain antibodies will play a key role in the future of pest management.”

About IBI Ag

IBI Ag is a pioneer in the agri-biotech industry, focused on delivering innovative, biological crop protection solutions. The company’s proprietary platform utilizes nano-bodies—a class of single-domain antibodies (VHHs)—to create selective, safe, and effective insect control products. These novel solutions have the potential to transform the agricultural industry by offering farmers an eco-friendly and cost-effective alternative to chemical pesticides, ultimately protecting the global food supply with a lower ecological footprint.

Founded by The Trendlines Group alongside Amir Ayali, PhD, and Rony Oren Benaroya, PhD, and supported by the Israel Innovation Authority, IBI Ag is poised to revolutionize crop protection with single-domain antibody technology.

The above content is referenced from FOX4, provided by EIN Presswire on Feb 13, 2025, 10:00 AM ET.